Contents Link Navigation Link

Targeting, Attacking, and Eradicating Cancers®

Welcome Message

Targeting, Attacking, and Eradicating Cancers®

Welcome to SillaJen.

Our mission is to be the global leader in oncolytic immunotherapeutics, providing effective therapy to cancer patients and addressing unmet medical needs. We are focused on engineering and developing best-in-class oncolytic virus immunotherapeutics by utilizing our proprietary SOLVE® platform which began in a collaboration with Jennerex in 2006.

SillaJen’s lead candidate Pexa-Vec (JX-594) is the first generation oncolytic vaccinia virus from our proprietary SOLVE® platform. Over 300 patients have been treated in Pexa-Vec in 13 clinical studies in multiple cancer indications.Pexa-Vec is currently in a multinational Phase 3 clinical trial (PHOCUS in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). In US, PHOCUS study is conducted under a special protocol assessment (SPA) granted by the US FDA.

Message from the CEOMarkMessage from the CEOMarkMarkMark

In addition, our oncolytic immunotherapeutics have shown synergy with chemotherapeutics and immune-oncology therapeutics to for greater efficacy with reduced toxicity.SillaJen and our partners have launched combination strategies with our lead candidate Pexa-Vec in various solid tumors including RCC and HCC.

Thank you for your interest and support of SillaJen.


  • Eun-Sang Moon, M.D., D.D.S
  • Chief Executive Officer